GORE® PRECLUDE®
Pericardial Membrane

DESIGNED TO MINIMIZE TISSUE ATTACHMENT

Evidence supporting improved reoperation: GORE® PRECLUDE® Pericardial Membrane for pericardial reconstruction or repair in conjunction with left ventricular assist device (LVAD) and other circulatory device patients

Together, improving life

GORE® PRECLUDE® Pericardial Membrane

Evidence supporting improved reoperation.

EFFECTIVE

Shown to facilitate reentry during reoperation.[1–14]

CONSERVES TIME

Reported to reduce reoperation time and ease explantation.[2,5,6,13]

SAFE

Demonstrated to have low risk of infection.[1–4, 7–9, 11–17]

15 clinical experiences

demonstrate efficacy and safety of utilizing GORE® PRECLUDE® Pericardial Membrane to support reoperations[1–5, 6–9, 12–17]

~2,900 patients

were reported to be implanted with GORE® PRECLUDE® Pericardial Membrane, **mostly to minimize tissue attachment**[1–18]

EFFECTIVE

According to results from clinical studies/reports utilizing GORE® PRECLUDE® Pericardial Membrane in total artificial heart (TAH) and LVAD surgeries:

100%

of patients were **free of severe adhesion at reoperation**[5, 11–13, 18]

Reoperation patients implanted with an LVAD or TAH and GORE® PRECLUDE® Pericardial Membrane	**N = 65**
Patients with severe adhesions	0 (0.0%)



Tissue attachment is known to lead to cardiac injury and increase reoperation time.

Image courtesy of Redo Valve Surgery Nowadays: What Have we Learned?, Acta Chirurgica Belgica, 103:5, 475-480, DOI: 0.1080/00015458.2003.11679470 Dr. Pierre Wauthy, Acta Chirurgica Belgica, © The Royal Belgian Society for Surgery, reprinted by permission of Taylor & Francis Ltd, http://www.tandfonline.com on behalf of The Royal Belgian Society for Surgery and Prof. Pierre Wauthy. Used with permission.

CONSERVES TIME

Results reported from a clinical study utilizing GORE® PRECLUDE® Pericardial Membrane while implanting a TAH demonstrate:[13]

GORE® PRECLUDE® Pericardial Membrane can reduce reoperation time substantially.[2,5,6,13]

>50%

decrease in time required to remove a TAH[13]

Reoperation steps	Average time without GORE® PRECLUDE® Pericardial Membrane[13]	Average time with GORE® PRECLUDE® Pericardial Membrane[13]
Removal of TAH	~2 hours	~0.5–1 hour
From incision to cannulation	84 minutes	57 minutes

"In the few patients who were reoperated, mediastinal and heart dissection was accomplished in a few minutes."[2]



Yau TM, Rao V. Facilitating reoperations using GORE® PRECLUDE® Pericardial Membrane to wrap left ventricular assist devices. Presented at Optimizing reoperation in LVAD patients utilizing GORE® PRECLUDE® Pericardial Membrane. A Gore webinar series for healthcare professionals; March 4, 2021; Toronto Ontario, Canada.

SAFE

According to published studies, LVAD and TAH implantations increase the risk of infection regardless of utilizing GORE® PRECLUDE® Pericardial Membrane during surgery.[19,20]

6.4% – 53.7%[21]

Meta analysis: infection rate range of LVAD and TAH surgeries

7.7%

clinical studies/reports utilizing GORE® PRECLUDE® Pericardial Membrane have shown an **infection rate within the range associated with LVAD and TAH surgeries**[5, 11–13, 18]

ORDERING INFORMATION

GORE® PRECLUDE® Pericardial Membrane.

Catalogue number	Nominal thickness (mm)	Nominal width (cm)	Nominal length (cm)
1PCM100	0.1	6	12
1PCM102	0.1	12	12
1PCM103	0.1	15	20

To schedule a meeting with a specialist or to place an order please contact your Gore Field Sales Associate or via:

U.S. toll free: 800 528 8763
Direct: 928 864 2927
PRECLUDEinformation@wlgore.com

References

1. Mestres C-A, Comas JV, Ninot S, *et al.* The use of polyetherurethane urea (Mitrathane) and polytetrafluoroethylene (Gore-Tex) membranes for pericardial closure: initial clinical results. *Thai Journal of Surgery* 1986;7(4):125-128.

2. Minale C, Nikol S, Hollweg G, Mittermayer C, Messmer BJ. Clinical experience with expanded polytetrafluoroethylene Gore-Tex surgical membrane for pericardial closure: a study of 110 cases. *Journal of Cardiac Surgery* 1988;3(3):193-201.

3. Amato JJ, Cotroneo JV, Galdieri RJ, Alboliras E, Antillon J, Vogel RL. Experience with the polytetrafluoroethylene surgical membrane for pericardial closure in operations for congenital cardiac defects. *Journal of Thoracic & Cardiovascular Surgery* 1989;97(6):929-934.

4. Loebe M, Alexi-Meskhishvili V, Weng Y, Hausdorf G, Hetzer R. Use of polytetrafluoroethylene surgical membrane as a pericardial substitute. *Texas Heart Institute Journal* 1993;20(3):213-217.

5. Holman WL, Bourge RC, Zorn GL, Brantley LH, Kirklin JK. Use of expanded polytetrafluoroethylene pericardial substitute with ventricular assist devices. *Annals of Thoracic Surgery* 1993;55(1):181-183.

6. Bacaner TJ, Young JN, DeCampli WM, Hardy C. Pericardial substitute and emergency resternotomy: life-saving combination. *Pediatric Cardiology* 1996;17(6):396-398.

7. Jacobs JP, Iyer RS, Weston JS, *et al.* Expanded PTFE membrane to prevent cardiac injury during resternotomy for congenital heart disease. *Annals of Thoracic Surgery* 1996;62(6):1778-1782.

8. Minale C, Hollweg G, Nikol S, Mittermayer CH, Messmer BJ. Closure of the pericardium using expanded polytetrafluoroethylene GORE-TEX surgical membrane: clinical experience. *Thoracic & Cardiovascular Surgeon* 1987;35(5):312-315.

9. Revuelta JM, Garcia-Rinaldi R, Johnston RH Jr, Vaughan GD 3rd. Implantation of pericardial substitutes. *Annals of Thoracic Surgery* 1985; 39(2):190-191.

10. Lahtinen J, Satta J, Pokela R, Nissinen J, Juvonen T. Pericardial closure with polytetrafluoroethylene surgical membrane or biodegradable polyglycolic acid mesh after coronary artery bypass surgery—a baseline report. *Annales Chirurgiae et Gynaecologiae* 1998;87(1):36-39.

11. Leprince P, Rahmati M, Bonnet N, *et al.* Expanded polytetrafluoroethylene membranes to wrap surfaces of circulatory support devices in patients undergoing bridge to heart transplantation. *European Journal of Cardio-thoracic Surgery* 2001;19(3):302-306.

12. Vitali E, Russo C, Tiziano C, Lanfranconi M, Bruschi G. Modified pericardial closure technique in patients with ventricular assist device. *Annals of Thoracic Surgery* 2000;69(4):1278-1279.

13. Copeland JG, Arabia FA, Smith RG, Covington D. Synthetic membrane neo-pericardium facilitates total artificial heart explantation. *Journal of Heart & Lung Transplantation* 2001;20(6):654-656.

14. Bezon E, Maguid YA, Gueret G, Choplain JN, Aziz AA, Barra JA. Wrapping of the left internal thoracic artery with an expanded polytetrafluoroethylene membrane. *Annals of Thoracic Surgery* 2006;8(1):383-385.

15. Alexi-Meskishvili V, Weng Y, Uhlemann F, Lange PE, Hetzer R. Prolonged open sternotomy after pediatric open heart operation: experience with 113 patients. *Annals of Thoracic Surgery* 1995;59(2):379-383.

16. Ozeren M, Han U, Mavioglu I, *et al.* Consequences of PTFE membrane used for prevention of re-entry injuries in rheumatic valve disease. *Cardiovascular Surgery* 2002;10(5):489-493.

17. Kajiwara H, Ichikawa Y, Yamazaki I, Uranaka Y, Hamada T. Experience with expanded polytetrafluoroethylene surgical membrane (Gore-Tex surgical membrane) for coronary artery bypass grafting does Gore-Tex surgical membrane induce postoperative mediastinitis? *ASAIO Journal* 2003;49(2):155.

18. Kornberger A, Walter V, Khalil M, *et al.* Suspected involvement of EPTFE membrane in sterile intrathoracic abscess and pericardial empyema in a multi-allergic LVAD recipient: a case report. *Journal of Cardiothoracic Surgery* 2015;10(1):99.

19. Holman WL, Skinner JL, Waites KB, Benza RL, McGiffin DC, Kirklin JK. Infection during circulatory support with ventricular assist devices. *Annals of Thoracic Surgery* 1999;68(2):711-716.

20. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. *New England Journal of Medicine* 1998;339(21):1522-1533.

21. Maniar S, Kondareddy S, Topkara VK. Left ventricular assist device-related infections: past, present and future. *Expert Review of Medical Devices* 2011;8(5):627-634.

Consult Instructions for Use
eifu.goremedical.com

INDICATIONS FOR USE: Reconstruction or repair of the pericardium. **CONTRAINDICATIONS:** Not for reconstruction of CARDIOVASCULAR DEFECTS such as cardiac, great vessel and peripheral vascular, DURA MATER, HERNIAS. Use of this product in applications other than those indicated has the potential for serious complications, such as suture pullout or failure of the repair (aneurysm formation). Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. ℞ Only

Products listed may not be available in all markets.

 22679206-EN AUGUST 2022

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 67332882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771